Topic Listing for SurModics

Acquisition Brookwood Pharmaceuticals Difficult Integrate Disrupt Business Dilute Acquisitions Future Undertake Difficult Integrate Disrupt Business Dilute
Acquisitions Investments Acquisitions Undertake Difficult Integrate Disrupt Business Dilute Shareholder
Adjustments Significant Events Administration
Adverse Results Clinical Trials Involving I-vation Intravitreal Implant Adverse Results Phase Trials I-vation Intravitreal Implant Harm
Aggregated Option Sar Exercises 2006 End Values Amended Restated 2003 Equity Incentive Plan
Amendment Plan Amendment Waivers
Annual Incentive Plan Annual Report
Arbitration Aron Anderson Phd
Arthur Tipton Phd Asset Impairment Charge
Assets Liabilities Measured Fair Value Recurring Basis Audit Committee
Audit Committee Report Audit Fees
Audit-related Fees Authority
Background Basis Presentation
Become Involved Expensive Unpredictable Patent Litigation Other Intellectual Beneficial Ownership Reporting Compliance
Biofx Laboratories Inc Board Directors Recommends Vote Each Proposal Below
Brian Robey Brookwood Pharmaceuticals Inc
Bruce Barclay Bryan Phillips
Cannot Adequately Protect Technologies Proprietary Information Unable Sustain Captions
Cash Equivalents Certain Relationships Related Transactions
Certification Pursuant 302 Sarbanes-oxley Act Certification Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Act
Certifications Change Control
Change Control Agreement Change Control Agreements
Change Control Arrangements Change Control Termination
Changes Level Instruments Measured Fair Value Recurring Basis Charles Olson
Coatings Drug Delivery Surface Modification Code Ethics Business Conduct
Coli Commitments Contingencies
Committee Board Meetings Compensation Benefits
Compensation Philosophy Objectives Competition
Consent Consent Independent Registered Public Accounting Firm
Construction Contractual Obligations
Convergence Medical Device Pharmaceutical Biotechnology Industries Cooperation Management
Corporate Governance Corporate Governance Nominating Committee Procedures Policy
Counterparts Critical Accounting Policies
Dale Olseth David Koch
Deferred Revenue Defined Contribution Plan
Definitions Deloitte Touche Llp
Dependent Key Personnel Not Able Attract Qualified Future Description
Description Espp Diagnostic Royalties
Director Attendance Policy Director Compensation 2007
Director Compensation 2009 Directors Fees
Disclosures Disclosure Documents Dna Protein Immobilization
Documents Incorporated Reference Douglas Astry
Drug Delivery Drug Delivery Surface Modification Competitive Markets Carry Risk
Drug Delivery Surface Modification Markets Duration Adjustments Modifications Terminations
Duration Plan Ease
Effective Date Plan Electronic Delivery Future Shareholder Communications
Eligibility Number Shares Employee Stock Purchase Plan
Employees Entire Agreement
Equity Compensation Plan Information Equity Ownership Guidelines
Equity Ownership Guidelines Executive Officers Establishing Executive Compensation
Estimates Exact Name Registrant Specified Charter
Except Per Share Data Exhibits Form 10-k
Face Liability Mishandle Improperly Dispose Hazardous Materials Used Face Product Liability Claims Related Participation Clinical Trials
Failure Expand Management Systems Controls Support Anticipated Growth Failure Identify Strategic Investment Acquisition Opportunities Integrate Acquired
Failure Identify Strategic Investment Acquisition Opportunities Limit Growth Fair Value Hierarchy
Federal Income Tax Consequences Federal Tax Considerations
Flexibility Form Letter Credit
Form Transfer Request Forward-looking Statements
Framework General Administrative Expenses
General Information Genomics Products
Geographic Revenue Gerald Fischer
Goodwill Governing Law
Government Regulation Grants Plan-based Awards 2007
Greement Hazardous Materials Some Research Development Manufacturing Processes
Held 2006 Hemo Biocompatibility
Hydrophilic Other Hydrophilic Technologies
Impairment Long-lived Assets Incentive Stock Option Plan
Income Tax Expense Income Tax Provision
Income Taxes Independent Registered Public Accounting Firm
Innorx Inc Intangible Assets
Integrated Framework Internal Control Integrated Framework
Internal Control-integrated Framework Introduction
Inventories Investment Obligation
Investment Purpose Investments
Jan Mwebster Jan Webster
John Benson John Meslow
José Bedoya Kendrick Melrose
Kenneth Keller Phd Land Purchase Commitment
Legal Description Legal Proceedings
Licensees Breach Agreements In-licensed Intellectual Property Others Deprived Licensing Arrangements
Limitation Change Control Payments Limited Experience Manufacturing Pharmaceutical Products Commercial Sale Subject
Limited Redundancy Manufacturing Facilities Lose Revenue Unable Maintain Liquidation
Liquidity Capital Resources Lise Duran Phd
Litigation Long -term Incentive Plans-awards Last
Long-term Success Business Suffer Unable Expand Licensing Base Loren Miller
Loss Major Customers Significantly Reduce Revenue Earnings Loss Significant Reduction Business Major Customers Significantly Reduce
Lubricity Major Customers
Majority Independent Directors Committees Management Shareholdings
Manufacture Supply Pharmaceutical Products Subject Product Liability Claims Manufacturing
Marketing Sales Medical Device Industry
Meeting Minutes Membership
Memorandum Purchase Agreement Merck Agreement
Michael Shoup Microarray Slide Products
Multiple Element Arrangements Multiple Surface Properties
Need Expand Licensing Base Reduce Reliance Several Major New Accounting Pronouncements
New Plan Benefits Non-foreign Transferors Certification Entity Transferor
Nonqualified Stock Option Plan Notice Annual Meeting Shareholders
Notices Obligation Exercise Option
Off-balance Sheet Arrangements Operating Segments
Ophthalmology Option Exercises Stock Vested
Option Sar Grants 2006 Organization Compensation Committee
Organization Compensation Committee Report Organization Compensation Committee Report Executive
Orthopedics Other Assets
Other Business Other Compensation
Other Income Net Outstanding Shares Voting Rights
Overview Part
Participants Patents Proprietary Rights
Paul Lopez Payment
Performance Awards Performance Share Awards
Peter Ginsberg Pharmaceutical Biotechnology Industries
Phd Philip Ankeny
Plan Benefits Potential Payouts Termination Change Control
Pre-approval Policies Procedures Principal Accountant Fees Services
Principal Shareholders Pro Forma
Procedures Shareholder Communications Directors Product Costs
Product Sales Products Incorporating Technologies Subject Continuing Regulations Extensive Approval
Products Subject Continuing Regulations Adverse Consequences Fail Comply Prohealing
Properties Property Equipment
Proxy Statement 2010 Annual Meeting Shareholders Report 2009 Purchased In-process Research Development
Purpose Quarterly Financial Data
Ratification Appointment Independent Registered Public Accounting Firm Proposal Reclassifications
Reclassifications Retroactive Adjustments Recognize Revenue Accordance Various Complex Accounting Standards Changes
Recombinant Human Antigens Regenerative Technologies
Related Person Transaction Approval Policy Rely Parties Market Distribute Sell Products Incorporating Technologies
Report Independent Registered Public Accounting Firm Research Development
Research Development Costs Research Development Expenses
Research Development New Technologies Adversely Affect Operating Results Responsibilities
Restricted Stock Awards Restricted Stock Plan
Restricted Stock Unit Awards Results Operation
Retirement Benefits Other Arrangements Dale Olseth Revenue
Revenue Arrangements Multiple Deliverables Revenue Harmed Cannot Purchase Sufficient Reagent Components Manufacture
Revenue Recognition Risks Relating Business Strategy Industry
Risks Relating Clinical Regulatory Matters Risks Relating Intellectual Property
Risks Relating Operations Reliance Parties Risks Relating Securities
Robert Buhrmaster Royalties License Fees
Sales Marketing Expenses Securities Exchange Act 1934
Selected Financial Data Sellers Documents
Selling General Administrative Expenses Shareholder Proposals
Sight Draft Signature Page Follows
Signature Page Memorandum Purchase Agreement Signatures
Significant Customers Single Manufacturing Facility Lose Revenue Unable Maintain Customer
Stabilization Products Steven Keough
Stock Stock Appreciation Rights
Stock Option Grants Stock Option Plans
Stock Performance Chart Stock Price Been Volatile Continue
Stock-based Compensation Subject Changes General Economic Conditions Beyond Control Including
Subsequent Events Subsidiaries
Substrates Successors Assigns
Summary Compensation Summary Compensation Arrangements Named Executive Officers
Summary Director Compensation Summary Plan
Surface Modification Competitive Market Carries Risk Technological Obsolescence Surface Modification Drug Delivery Competitive Markets Carry Risk
Surface Modification Drug Delivery Markets Surmodics Coating Technologies Applications
Surmodics Coating Technologies Clinical Benefits Surmodics Coating Technologies Overview
Surmodics Coating Technologies Product Development Benefits Surmodics Drug Delivery Surface Modification Technologies Applications
Surmodics Drug Delivery Surface Modification Technologies Clinical Benefits Surmodics Inc
Surmodics Inc 2009 Equity Incentive Plan Surmodics Inc Board Compensation Policy
Surmodics Inc Notice Annual Meeting Shareholders Systemic Local Drug Delivery Through Injectable Microparticles Implants
Table Contents Tax Fees
Term Agreement Terms Conditions Incentive Stock Options
Terms Conditions Nonqualified Stock Options Tissue Engineering
Transactions Related Persons Transferability
Types Awards Ultra-web
Ultra-web Synthetic Extracellular Matrix Ecm Unable Keep Trade Secrets Confidential Technology Proprietary Information
Valuation Long-lived Assets Vitro
Vitro Products Vitro Technologies
Vivo Vote Internet Wwwproxyvotecom
Vote Mail Vote Phone 1-800-690-6903
Wettability Withholding Taxes
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki